The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...
Analyst Andrew Fein of H.C. Wainwright maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), boosting the price target to ...
Journavx is the first and only approved non-opioid oral painkiller and the first new class of pain medicine approved in more ...
Vertex Pharmaceuticals (VRTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Terence ...
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has ...
Vertex has gained the FDA's approval for its non-addictive pain med Journavx, which becomes the first significant innovation ...
The FDA has approved Vertex Pharmaceuticals’ oral Journavx (suzetrigine) to treat adults with moderate-to-severe acute pain.
Despite high demand for an option like Journavx, doctors fear the drug’s price could be a major hangup for insurers, ...
The new non-opioid drug has been approved for the treatment of severe pain, such as that following surgery or an injury.
Vertex Pharmaceuticals on Thursday won approval from the Food and Drug Administration for a non-opioid pain drug, clearing ...
US Federal officials have approved a new pain pill by Vertex Pharmaceuticals called Journavx, aimed at reducing addiction and ...
The greenlight for Journavx (suzetrigine), which comes on the heels of a $7.4 billion opioid settlement, could spark momentum ...